PAVM vs UNH

PAVmed Inc. (PAVM) remains a highly speculative, high-risk, high-reward investment, yet its financial runway has materially improved since the last analysis. The completion of a $30M Series D preferred stock and $15M senior secured note financing provides a crucial $45M capital infusion, significantly alleviating the immediate cash burn and precarious financial position that previously justified a...

UnitedHealth Group (UNH) remains a healthcare titan, but its sheer scale and the highly regulated nature of its operations fundamentally limit its 10x growth potential within 3-5 years. The recent Optum Health operating loss of $278M in 2025 (compared to $7.77B income in 2024) is a significant concern, eroding the growth narrative that Optum once provided. Furthermore, the proposed 0.09% Medicare ...